Table 1.

Characteristics and quality scores of included studies.

						Sex (male/female)		Intervention regimen
First author (year)	Design	Location	Number of patients	Number of eyes	Mean age	Combination	Surgery only	Surgery	Bevacizumab	Follow-up (mo)	Quality score (%)
Mahdy (2013)	RCT	Egypt	40	40	55/56	12/8	11/9	AGVI	1.25 mg/0.05 ml	18/18	78.1
Eid (2009)	Pro	Saudi Arabia	30	30	56.0/53.7	ns	ns	AGVI	1.25 mg/0.05 ml	12.5/16.4	65.6
Ma (2012)	Retro	Korea	48	52	ns	11/9 (eyes)	16/16 (eyes)	AGVI	1.25 mg/0.05 ml	12/12	62.5
Kang (2013)	Retro	Korea	26	27	54.8/54.3	11/3	11/2	AGVI	1.25 mg/0.05 ml	6/6	50
Sevim (2013)	Retro	Turkey	41	41	65.5/65.8	11/8	13/9	AGVI	1.25 mg/0.05 ml	12/12	68.8
Zhou (2013)	Retro	China	53	53	54.4/57.9	14/11	22/6	AGVI	2.5 mg/0.1 ml	15.1/15.4	65.6
Arcieri (2015)	RCT	Brazil	40	40	59.3/62.4	13/7	11/9	AGVI	1.25 mg/0.05 ml	25.8/28.2	80.2
Olmos (2016)	Retro	USA	151	163	66.1/63.7	27/37	58/41	AGVI	1.25 mg/0.05 ml	12/12	70.3
Kwon (2017)	Retro	Korea	70	70	59.1/57.2	38/7	18/7	AGVI	1.25 mg/0.05 ml	26/27	69.9

AGVI = Ahmed glaucoma valve implantation, Pro = prospective study, RCT = randomized control trial, Retro = retrospective study.